Dr. Lutz, Physiatrist-in-Chief Emeritus for the Hospital for Special Surgery, assumes responsibility for clinical aspects of the brtxDISC™ Program
JUPITER, Fla.--(BUSINESS WIRE)--BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB:BRTX), a life sciences company focused on adult stem cell-based therapies for various personal medical applications, today announced that it has entered into a consulting agreement with Gregory Lutz, M.D. pursuant to which Dr. Lutz will serve as Chief Medical Advisor for Spine Medicine.
"I have spent many years treating patients suffering from back problems and working on regenerative medical therapies, but there are limited non-surgical, efficacious alternatives. BioRestorative's brtxDISC™ program represents a potential breakthrough treatment and I am very excited to begin my association with the Company."
Dr. Lutz will be responsible for advancing the Company's brtxDISC™ Program including preparing the Company's Investigational New Drug/Investigational Device Exemption application with the U.S. Food and Drug Administration (FDA). In addition, Dr. Lutz will lead the efforts to design the trial protocol, identify trial sites and assist in the selection of a contract research organization (CRO) to conduct the studies. Dr. Lutz also will interact on the Company's behalf with the FDA and the investment community.
Dr. Lutz is Associate Professor of Clinical Rehabilitation Medicine at Weill Medical College of Cornell University in New York City, and an attending physician at the Hospital for Special Surgery. In 1997 Dr. Lutz founded the Physiatry Department at the Hospital for Special Surgery and became its first Physiatrist-in-Chief. He is currently the Physiatrist-in-Chief Emeritus for the Hospital for Special Surgery and is a member of the board of trustees. He is also the consulting physician to the National Hockey League Players' Association.
He has more than 35 peer-reviewed articles to his credit, many of which involve research on lumbar pain and herniated discs.
Mark Weinreb, Chief Executive Officer of BioRestorative Therapies, said, "We are delighted to be able to work with Dr. Lutz, who is a leader in the field of Physical Medicine & Rehabilitation, and a specialist in treating spine disease. We expect that his leadership role as Chief Medical Advisor for the program and his considerable experience in this field will assist the Company in receiving the approvals needed to start clinical trials and offer our non-surgical treatment for repairing injured painful discs to millions of sufferers."
Dr. Lutz said, "I have spent many years treating patients suffering from back problems and working on regenerative medical therapies, but there are limited non-surgical, efficacious alternatives. BioRestorative's brtxDISC™ program represents a potential breakthrough treatment and I am very excited to begin my association with the Company."
Dr. Lutz received his medical degree from Georgetown University and was awarded the Margaret M. Kenrick Achievement Award in Physical Medicine & Rehabilitation. He pursued his specialty training in Physical Medicine & Rehabilitation at the Mayo Clinic in Rochester, Minn. Following his residency he completed an Orthopedic Sports Medicine Fellowship at the Hospital for Special Surgery. Dr. Lutz has been in practice at the Hospital for Special Surgery since 1993.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops products and medical procedures using cell and tissue protocols, primarily involving adult stem cells, including:
brtxDISC™ (Disc Implanted Stem Cells) is an investigational non-surgical treatment for bulging and herniated lumbar discs that is intended for patients who have failed non-invasive procedures and face the prospect of surgery. The treatment involves culturing a patient's own stem cells and then delivering them via a proprietary medical device to the damaged region of the disc in an outpatient procedure.
ThermoStem® is a treatment using brown fat stem cells that is under development for metabolic disorders including diabetes and obesity. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels.
brtx-C Cosmetic is based on the development of a human cellular extract that has been demonstrated in in vitro skin studies to increase the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Contacts
Investors:
LHA
Kim Sutton Golodetz, 212-838-3777
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]